Inclusion Criteria:  Participant has given written informed consent. Participant has sufficient knowledge of the English language to be able understand the participant information sheet and trial materials including outcome assessments. Participant is aged ≥18 years and <80 years at the time of screening visit. Participant is taking between 1 to 3 antihypertensive medications (inclusive) at time of screening and baseline (randomisation) visit and is willing to adhere to no change in medication during the trial until end of the trial visit (visit 5). Participant has confirmed diagnosis of hypertension.  Participant meets BP criteria:  • 24-hour ambulatory BP monitoring (ABPM) at either screening visit or baseline (randomisation) visit, with mean daytime SBP of ≥135 mmHg and <170 mmHg and mean daytime DBP of >85 mm Hg and <115 mmHg (N.B. By default, Ambulatory Blood Pressure Monitoring [ABPM] at screening visit will be used at baseline visit. However, if there has been an addition of new medication after participants screening visit, 24-hour ABPM must be repeated at baseline visit).  AND  • Mean office BP (which is mean of last two readings from 3 BP recordings) with recorded SBP of ≥140 mmHg and <180 mmHg and DBP ≥90 mmHg and <120 mmHg at screening or baseline (randomisation) visit (either one of the two visits or both).  Participant has one or more of the following associated conditions:  Obesity: BMI >30 or waist circumference >94 cm (men) or > 80cm (women). (NB. For participants of South-East Asian/Chinese/Japanese origin these cut-offs are >90 cm (men) or >80 cm (women)). Type 2 diabetes - controlled or sub-optimally controlled (HbA1c ≤8.5% or ≤69 mmol/mol) on diet and/ or medications except insulin. Heart rate (average) ≥70 bpm at screening or baseline (randomisation) visit (measurement taken after 5 minutes of rest in a seated position and when finger probe has been placed for a minimum of 30 seconds thereafter) or a heart rate (average) ≥60 bpm at screening or baseline (randomisation) visit if the patient is taking beta-blocker medication. HbA1c ≥42 mmol/mol or fasting blood glucose (if available) ≥5.6 mmo/L AND either low HDL cholesterol (≤1.03 mmol/L for men and ≤1.29 mmol/L for women) or high triglyceride (triglycerides ≥1.7 mmol/L) Both low HDL cholesterol (≤1.03 mmol/L for men and ≤1.29 mmol/L for women) AND high triglyceride (triglycerides ≥1.7 mmol/L) Diagnosed or known case of polycystic ovarian syndrome. Female participants of child-bearing potential (all those below 55 years except if they are surgically sterile, meaning they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy, or formally diagnosed by their doctors to be post-menopausal) must agree to use the acceptable methods of contraception from the time of consent until last follow up visit. Participant is able to communicate satisfactorily with the Investigator and Investigation Site staff, and to participate in, and comply with all clinical study requirements. Participants agrees to have all trial procedures performed and is able and willing to comply with all trial visits and protocol requirements.  Exclusion Criteria:  Participant is unable and unwilling to use the AffeX-CT device daily. Participant has a small tragus precluding reliable application of tAN using the AffeX-CT device. Participant is diagnosed with atrial fibrillation or other form of cardiac arrhythmia Participant is known to have chronic kidney disease (CKD) stage 3b or higher or had eGFR <45 ml/min/1.73 m2 in last three months prior to baseline (randomisation) visit. Participant has type 1 diabetes mellitus. Participant has type 2 diabetes mellitus on Insulin or those on oral antidiabetic medications with poor glycaemic control defined as HbA1c above 8.5% (or >69 mmol/mol). Participant has a history of falls or symptoms of orthostatic hypotension in the last 3 months prior to baseline (randomisation) visit. Participant is pregnant, nursing or planning to become pregnant within the next 6 months. Participant suffers from chronic pain and has taken anti-inflammatory drugs for two or more days per week over the last month prior to baseline (randomisation) visit. Participant has significant (or symptomatic) target organ damage including symptomatic heart failure, renal damage, symptomatic peripheral vascular disease, or severe retinopathy. Participant has a history of stable or unstable angina or had an acute coronary event within 3 months prior to baseline (randomisation) visit or had a myocardial infarction within the last six months of enrolment prior to baseline (randomisation) visit. Participant has history of renal denervation within 1 year prior to baseline (randomisation) visit. Participant has history of hospitalization for heart failure, cerebrovascular accidents, or stroke (at any time in the past). Participant has mean office pulse pressure ≥ 80 mmHg (mean of the last two of the three readings) at screening or baseline (randomisation) visit. Participant has a heart rate <50 bpm at screening or baseline (randomisation) visit (measurement taken after 5 minutes of rest in a seated position and when finger probe has been placed for a minimum of 30 seconds thereafter). Participant has auricular dermatitis. Participant has postural hypotension, defined as a fall > 20mmHg in SBP on standing at 3 minutes (compared with sitting). Participant has a history of hospitalization for hypertensive emergency or urgency in the last six months of enrolment prior to baseline (randomisation) visit. Participant is identified as unsuitable to participate by the CI/Co-Investigator(s) and/or Investigation site team for another reason (e.g., for other medical reasons, laboratory abnormalities, limited life expectancy, etc.).